Contact
Let’s get in contact
Avatar

Julia Pizzolato PhD

Commercial Scientific Liaison

Mail:

jpi@evitria.com

Location:

Zurich, CH

LinkedIn Profile

Julia Pizzolato, PhD (University of Zurich), works at the intersection of protein engineering, antibody design, and data science. She brings experience across biotherapeutics R&D, protein characterization, and biomanufacturing analytics. In her role at evitria AG, she supports customers and project teams with technical consultation, feasibility assessments, and training materials—helping R&D teams make faster, data-informed decisions.

Career highlights

  • Commercial Scientific Liaison, evitria AG (Jan 2026–present): Technical consultation, feasibility checks, and scientific training materials for complex client projects in antibody engineering and recombinant protein expression.
  • Senior Scientist in Antibody Engineering, InCephalo (May 2022–Nov 2024): Led protein design, purification, and characterization (ELISA, bioactivity assays, flow cytometry) for immuno-oncology programs and guided strategy decisions with literature/patent synthesis.
  • Senior Scientist / Technical Expert Data Management, CSL Behring (Oct 2020–Sep 2021): Built analytics pipelines used daily by scientists; delivered technical training and support for data integration.
  • Head of Business Development | Data Scientist, Propulsion Academy Zurich (Jan 2020–Aug 2020): Taught data science (SQL, BigQuery) and delivered large-scale training sessions with strong participant feedback.
  • Research Scientist, Heptares Therapeutics Zurich (Dec 2017–Jan 2019): Engineered thermostable GPCR variants while operating effectively within a matrixed organizational environment.

Publications

Julia has published peer-reviewed research in molecular biology and DNA repair, including articles in Nature Communications and The Journal of Biological Chemistry. This track record underpins her approach to evidence-based writing, with a strong focus on experimental rigor and clear data interpretation. Selected publications are listed below, with additional references available via ResearchGate.

  1. FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2 (Oct. 2017)
    Interstrand cross-link (ICL) hypersensitivity is a characteristic trait of Fanconi anemia (FA). Although FANCD2-associated nuclease 1 (FAN1) contributes to ICL repair, FAN1 mutations predispose to karyomegalic interstitial nephritis (KIN) and cancer rather than to FA. Thus, the biological role of FAN1 remains unclear. Because fork stalling in FAN1-…view
  2. FANCD2-associated Nuclease 1, but Not Exonuclease 1 or Flap Endonuclease 1, Is Able to Unhook DNA Interstrand Cross-links in Vitro (Jul 2015)
    Cisplatin and its derivatives, nitrogen mustards (NMs) and mitomycin C (MMC) are widely used in cancer chemotherapy. Their efficacy is linked primarily to their ability to generate DNA interstrand cross-links (ICLs), which effectively block the progression of transcription and replication machineries. Release of this block, referred to as unhooking…view
  3. Stochastic signalling rewires the interaction map of a multiple feedback network during yeast evolution (Feb. 2012)
    During evolution, genetic networks are rewired through strengthening or weakening their interactions to develop new regulatory schemes. In the galactose network, the GAL1/GAL3 paralogues and the GAL2 gene enhance their own expression mediated by the Gal4p transcriptional activator. The wiring strength in these feedback loops is set by the number of…view
  4. Supplementary Information (Feb. 2012)
    Supplementary Figures S1-S3 and Supplementary Tables S1-S5 view

Articles written by Julia Pizzolato PhD (37)

Julia writes about recombinant antibody production and CHO transient expression, antibody fundamentals (e.g., IgG), Fc biology and effector functions (e.g., ADCC), and complex modalities such as bispecific and multispecific antibodies. Her articles are designed to support practical R&D decision-making and are grounded in primary literature and evitria’s operational experience. Content is reviewed and updated as technical standards, terminology, or best practices evolve.